Australian Child Undergoes Stem Cell Therapy in Thailand for Rare Eye Condition

A five-year-old Australian child diagnosed with a rare eye condition underwent stem cell therapy in Thailand in 2023. His mother reported observing improvements in his vision following the treatment, which is not available in Australia due to regulatory restrictions. Medical experts acknowledge the potential of stem cell research in ophthalmology but caution against unapproved overseas therapies that lack robust clinical trial data.

Reid's Rare Diagnosis: Septo-Optic Dysplasia

Reid, from Port Macquarie, New South Wales, was diagnosed in 2021 with septo-optic dysplasia (SOD) with optic nerve hypoplasia. This rare condition affects optic nerve development, leading to significant visual impairment. Doctors initially indicated that his vision would be severely limited, potentially only allowing him to detect if an LED light was on or off. Reid remains legally blind.

Pursuing Unapproved Therapy Abroad

In 2023, Reid's mother, Sarah Hardy, decided to pursue stem cell therapy for her then-two-year-old son in Bangkok, Thailand. The decision followed personal research and consultations with specialists and other families. One medical professional reportedly advised against the procedure due to concerns regarding its efficacy and the approximately $50,000 cost, which included travel. Other medical professionals reportedly assisted Ms. Hardy with her research.

Such stem cell therapies are not available in Australia. Regulations in Australia are strict, and many stem cell treatments lack local clinical trial approval to demonstrate safety and effectiveness.

Mother Reports Significant Visual Changes

Following several rounds of the procedure, Ms. Hardy reported observing changes in Reid's vision. These reported changes included an increased awareness of people entering a room, such as noticing his father and inquiring about him, and later stating he could perceive his mother's smile. Ms. Hardy described these changes as contributing to Reid's increased independence and safety.

Vision assessments conducted before and after the treatment reportedly indicated an improvement in visual acuity over two years, moving from 1/60 (classified as profound vision impairment) to 3/60 (classified as severe vision impairment). Reid, who started school this year and uses Braille, continues to be legally blind. Ms. Hardy stated her satisfaction with the decision to seek overseas treatment.

Expert Cautions and Research Potential

Professor Megan Munsie, an expert in emerging stem cell technologies at the Melbourne Medical School and the Murdoch Children's Research Institute, noted that stem cell therapies constitute a rapidly growing field with established applications in conditions such as leukaemia in Australia. However, Professor Munsie cautioned that many treatments advertised overseas have not undergone clinical trials or received approval in Australia.

She highlighted the importance of robust research to validate efficacy and safety, warning against clinics that may not be using actual stem cells or making unsubstantiated claims.

Professor Munsie advised individuals considering overseas treatments to consult their doctors and cautioned against viewing stem cells as a universal cure, noting the challenge of controlling their behavior in the body.

Professor Alex Hewitt, a specialist in genetic eye diseases at the University of Tasmania, stated that there is no clear indication for a beneficial stem cell-based therapy specifically for septo-optic dysplasia. However, he also identified the eye as a promising area for stem cell research. He noted that its relatively small size may simplify cell replacement therapies, requiring fewer cells. Professor Hewitt confirmed that no stem cell therapies currently treat eye conditions in Australia.

Regulatory Hurdles and Future Aspirations

Beike Biotechnology, the provider of the treatments in Thailand, did not respond to requests for comment regarding its work or Reid's specific treatment. Ms. Hardy has expressed hope that further stem cell treatments, similar to the one Reid received, may become available in Australia in the future.